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Abstract
Purpose—Although fatigue is a common problem for men with prostate cancer undergoing 
androgen deprivation therapy (ADT), there has been little systematic research on this issue. The 
present study examined changes in fatigue among prostate cancer patients receiving ADT 
compared to controls and predictors of heightened fatigue in ADT patients.
Methods—Prostate cancer patients treated with ADT (ADT+ group, n=60) completed 
assessments of fatigue prior to or just after ADT initiation (baseline) and 6 and 12 months later. 
Prostate cancer patients treated with prostatectomy only (ADT− group, n=85), and men without 
cancer (CA− group, n=86) matched on age and education completed assessments at similar 
intervals.
Results—Group-by-time interactions for fatigue severity, interference, and duration were 
observed when comparing the ADT+ group to controls. Groups did not differ at baseline; however, 
the ADT+ group reported worse fatigue at 6 and 12 months. The same pattern was observed for 
changes in the prevalence of clinically meaningful fatigue and the extent of clinically meaningful 
change in fatigue. Within the ADT+ group, higher baseline comorbidity scores were associated 
with greater increases in fatigue interference and higher baseline Gleason scores were associated 
with greater increases in fatigue duration.
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Conclusions—Prostate cancer patients receiving ADT demonstrate a trajectory of worsened 
fatigue during the first 12 months following treatment initiation relative to controls. Greater 
comorbidities and higher Gleason scores at baseline appear to be risk factors for heightened 
fatigue during the first year following ADT initiation. Results highlight important time points for 
implementation of interventions aimed at fatigue reduction.
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Introduction
Androgen deprivation therapy (ADT) is a hormonal treatment administered to men with 
prostate cancer. ADT serves to stop or delay subsequent cancer growth and metastasis by 
depriving tumor cells the stimulating effects of androgens. Men receiving this treatment 
typically experience a variety of negative side effects, including hot flashes and loss of 
muscle mass [1–4].
Reports also suggest that fatigue commonly affects men with prostate cancer receiving ADT. 
Along these lines, studies consistently indicate that fatigue worsens over time following 
ADT initiation [5–7]. Moreover, as many as 43% of patients treated with ADT have been 
reported to experience clinically significant fatigue [8]. Although these studies provide 
useful information, they are characterized by a number of methodologic limitations that 
include small sample sizes, limited follow-up periods, lack of a non-cancer comparison 
group, and/or lack of a comparison group of prostate cancer patients not receiving ADT. In 
one of the most rigorous studies to date, Alibhai and colleagues [9] showed that ADT 
recipients experienced greater decrements in vitality over the course of 12 months compared 
to men with prostate cancer not receiving hormonal therapy and noncancer controls. There 
are reasons to believe, however, that reduced vitality is not equivalent to heightened fatigue 
and that fatigue is better assessed using measures designed specifically for that purpose [10].
The present study addresses these limitations by prospectively examining changes in fatigue 
during a one-year period following ADT initiation using a validated and multidimensional 
measure of fatigue. In addition, the present study included matched comparison groups 
consisting of men with prostate cancer not treated with ADT and men with no history of 
cancer. The study had three aims. First, we sought to build upon prior literature by 
investigating the trajectory of fatigue among men with prostate cancer during the 12 months 
following ADT initiation while simultaneously assessing fatigue among men in the two 
control groups. We hypothesized that men in the ADT group would report worsening fatigue 
over time compared to prostate cancer patients who did not receive ADT and men without 
cancer. The second aim was to examine changes in the prevalence of clinically meaningful 
fatigue and the extent of clinically meaningful changes in fatigue among men in the ADT 
group compared to men in the two control groups. We hypothesized that clinically 
meaningful fatigue would become more prevalent over time in men treated with ADT 
compared to men in the control groups and that men treated with ADT would be more like 
to experience clinically meaningful increases in fatigue over time. A third aim was to 
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conduct exploratory analyses to investigate demographic and clinical predictors of changes 
in mean-level fatigue over time among men receiving ADT.
Methods
Participants
Three samples of participants were recruited as part of a larger, longitudinal study 
investigating cognitive side effects of ADT: men receiving ADT for the treatment of prostate 
cancer (ADT+ group), men receiving prostatectomy only for the treatment of prostate cancer 
(ADT− group), and men with no history of cancer (CA− group). Eligibility criteria required 
that all participants: be at least 18 years of age, be able to speak and read English, have at 
least an eighth grade education, have no history of stroke, and be free of cognitive 
impairment (Short Portable Mental Status Exam score < 3) [11]. Additional eligibility 
criteria for the ADT+ group were that they: be diagnosed with non-metastatic or 
asymptomatic metastatic prostate cancer, be scheduled to start or have started ADT in past 
month, be scheduled to received ADT for at least 6 months, have not received treatment for 
any other cancers in the 12 months prior to recruitment, have no history of brain cancer or 
previous treatment with cranial irradiation, and have not been treated with ADT in the 12 
months prior to recruitment or an anti-androgen agent (e.g., bicalutamide) in the 6 months 
prior to recruitment. Additional eligibility criteria for the ADT− group were that they: be 
diagnosed with non-metastatic prostate cancer, have no history of other cancers except non-
melanoma skin cancer, have undergone prostatectomy, have no history of recurrent disease 
since undergoing prostatectomy, have no history of other forms of prostate cancer treatment 
(e.g., radiotherapy), not be scheduled for additional prostate cancer treatment, and not be 
receiving testosterone supplementation. Additional eligibility criteria for CA− group were 
that they: have no history of any form of cancer except non-melanoma skin cancer, not be 
receiving testosterone supplementation, and have a working telephone number.
Procedures
ADT+ and ADT− participants were recruited from Moffitt Cancer Center. ADT+ 
participants were also recruited from the James A. Haley Veterans’ Hospital. CA− 
participants were identified through use of information obtained from Marketing Systems 
Group, Inc. (Fort Washington, PA) and were initially contacted by telephone; those eligible 
and interested were scheduled for an appointment at which written informed consent was 
obtained. Eligible ADT− patients were matched to ADT+ participants on age (within 5 
years), educational level (≤12 years, 13–16 years, or ≥17 years), and time since prostate 
cancer diagnosis (within 6 months). Eligible CA− men were matched to ADT+ participants 
on age and education. Baseline assessments were completed by ADT+ participants before or 
within 21 days of starting ADT and 6 and 12 months later. ADT− and CA− participants 
were assessed at similar time intervals. See Supplementary Figures 1 – 3 for information 
about participant flow. The larger number of participants in the ADT− and CA− groups 
relative to the ADT+ group reflects that, for ADT+ participants whose ADT− or CA− 
matched control withdrew from the study, an additional matched control was recruited in 
order to obtain data at all three assessments. Data were collected between September 2008 
and October 2013. Written informed consent was obtained prior to initiation of study 
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procedures. Participants were paid $80 at each evaluation. This study was approved by the 
Institutional Review Board at the University of South Florida.
Measures
Demographic and Clinical Characteristics—Demographic information was collected 
at baseline via self-report. Medical comorbidities were assessed at baseline using a self-
report version of the Charlson Comorbidity Index [12]. Clinical information for the ADT+ 
and ADT− groups was collected via medical record review.
Fatigue—Participants completed the 14-item Fatigue Symptom Inventory (FSI) at each 
time point. The FSI assesses 3 domains of fatigue: severity, interference, and duration [13]. 
Fatigue severity represented the average of 4 items assessing the most, least, average, and 
current level of fatigue experienced. Fatigue interference represented the average of 6 items 
assessing the extent to which fatigue interfered with the participant’s general level of 
activity, ability to bathe and dress, normal work activity, ability to concentrate, relations with 
other people, and enjoyment of life. The two items assessing fatigue duration (number of 
days fatigued, amount of time fatigued per day) were scored as separate outcomes for the 
purposes of this project. Consistent with National Comprehensive Cancer Network 
guidelines [14], the presence of clinically meaningful fatigue was defined as scores ≥ 4 for 
the average of the fatigue severity items. The FSI has been found to be a valid and reliable 
measure among cancer populations [15].
Statistical analyses
Chi-square and t-tests were used to determine if there were group differences on 
demographic or clinical factors. Variables found to differ between groups (p <.10) were 
included as covariates in all subsequent analyses that involved group comparisons. Mixed 
models analyses were conducted to test the hypothesis that the ADT+ group would 
experience greater increases in fatigue over time compared to the control group as evidenced 
by a significant group by time interaction. Significant interactions were followed up with 
examination of group differences at baseline, 6 months, and 12 months and additional mixed 
models examining within-group change over time. Generalized estimating equation models 
were conducted to examine differences in the prevalence of clinically meaningful fatigue 
over time between groups. Chi-squares were used to examine group differences in 
prevalence of clinically meaningful fatigue at baseline, 6 months, and 12 months. In a 
second approach to this issue, chi-squares were used to examine clinically meaningful 
changes in fatigue over time adopting as a criterion a 1 SD change in fatigue from baseline 
to the 6 and 12 month follow-ups. Finally, linear regression analyses were conducted to 
identify baseline demographic and clinical predictors of increases in fatigue over time in the 
ADT+ group. Baseline fatigue was entered first into each analysis to create a residualized 
change score, followed by demographic or clinical predictors. The 12 month fatigue value 
served as the dependent variable. A p value of .05 was considered statistically significant. 
Data analyses were performed using SAS Version 9.3 (Cary, NC).
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Results
Demographic and Clinical Characteristics
Participants included 60 men in the ADT+ group, 85 men in the ADT− group, and 86 men in 
the CA− group. Demographic and clinical characteristics are shown in Table 1. As 
anticipated, Gleason scores were higher in the ADT+ group than the ADT− group (p < .
001). The ADT+ group was less likely to be white (p values ≤ .03) and married (p values ≤ .
04) than the ADT− or CA− groups. The ADT+ group was also less likely to have attended 
college than the ADT− group (p = .05) and reported more comorbidities than men in the 
ADT− group (p = .02). Therefore, race, marital status, education, and comorbidities were 
entered as control variables in all subsequent analyses.
Consistent with previous studies [16–17], fatigue outcomes were first compared between the 
ADT− and CA− groups to determine whether they could be combined into a single control 
group, thereby increasing statistical power and decreasing the number of tests performed. 
The ADT− and CA− groups did not differ on any fatigue outcome at any time point (ps ≥ .
37) or on change over time in any fatigue outcome (ps ≥ .43). Therefore, in all subsequent 
analyses the ADT− and CA− groups were combined into a single control group.
Changes in Fatigue Severity, Interference, and Duration
Figure 1a depicts adjusted group means for fatigue severity. Although the ADT− and CA− 
groups were combined for analytic purposes, their separate means are depicted for 
illustrative purposes. A group by time interaction was observed when comparing the ADT+ 
group to the control group (p = .02). No group differences in fatigue severity were evident at 
baseline (ADT+ group M = 2.18, SE = 0.25; CA− group M = 2.11, SE = 0.14; p = .93) or 6 
months (ADT+ group M = 2.62, SE = 0.22; CA− group M = 2.20, SE = 0.12; p = .18); 
however, the ADT+ group reported greater fatigue severity than controls at 12 months (ADT
+ group M = 3.06, SE = 0.26; CA−group M = 2.29, SE = 0.14; p = .02). Examination of 
within-group change indicated that fatigue severity worsened over time in the ADT+ group 
(p < .001), but did not change over time in the control group (p ≥ .15).
Figure 1b depicts adjusted group means for fatigue interference. A group by time interaction 
was observed when comparing the ADT+ group to the control group (p = .002). No group 
differences in fatigue interference were evident at baseline (ADT+ group M = 1.34, SE = 
0.27; CA− group M = 0.90, SE = 0.11; p = .23); however, the ADT+ group reported greater 
fatigue interference at 6 (ADT+ group M = 1.77, SE = 0.24; CA− group M = 0.96, SE = 
0.10; p = .004) and 12 months (ADT+ group M = 2.21, SE = 0.27; CA− group M = 1.02, SE 
= 0.11; p < .001) compared to controls. Examination of within-group change indicated that 
fatigue interference worsened over time in the ADT+ group (p < .001), but did not 
significantly change in the control group (p ≥ .20).
Figure 1c depicts adjusted group means for the number of days participants felt fatigued. A 
group by time interaction was observed when comparing the ADT+ group to the control 
group (p < .001). No group differences in number of days fatigued were evident at baseline 
(ADT+ M = 2.01, SE = 0.29; CA− group M = 2.12, SE = 0.15; p = .71); however, men in the 
ADT+ group reported a greater number of days fatigued at both 6 (ADT+ group M = 2.78, 
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SE = 0.26; CA− group M = 2.19, SE = 0.13; p = .03) and 12 months (ADT+ group M = 
3.54, SE = 0.30; CA− group M = 2.26, SE = 0.15; p < .001) compared to controls. 
Examination of within-group change indicated that the number of days participants felt 
fatigued worsened over time in the ADT+ group (p < .001), but did not significantly change 
in the control group (p ≥ .33).
Figure 1d depicts adjusted group means for the amount of time participants felt fatigued per 
day. A group by time interaction was observed (p = .05). No group differences in amount of 
time felt fatigued per day were evident at baseline (ADT+ group M = 2.30, SE = 0.29; CA− 
group M = 1.85, SE = 0.14; p = .21); however, men in the ADT+ group reported a greater 
amount of fatigue per day at both 6 (ADT+ group M = 2.67, SE = 0.25; CA− group M = 
1.91, SE = 0.12; p = .01) and 12 months (ADT+ group M = 3.04, SE = 0.29; CA− group M 
= 1.96, SE = 0.14; p = .002) compared to controls. Examination of within-group change 
indicated that the amount of time participants felt fatigued worsened over time in the ADT+ 
group (p = .01), but did not change in the control group (p ≥ .41).
Changes in the Prevalence of Clinically Meaningful Fatigue and the Extent of Clinically 
Meaningful Change in Fatigue Over Time
Figure 2 depicts the prevalence of clinically meaningful fatigue by group over time. A group 
by time interaction was observed (p = .02) indicating that change over time in the prevalence 
of clinically meaningful fatigue differed by group status. At baseline, 12% of ADT+ patients 
reported clinically meaningful fatigue compared to 16% of men in the control group (χ2 = .
60, p = .44). At 6 months, 33% of men in the ADT+ group reported clinically meaningful 
fatigue compared to 21% of men in the control group (χ2 = 3.74, p = .05). At 12 months, 
32% of men in the ADT+ group reported clinically meaningful fatigue compared to 19% of 
the control group (χ2 = 4.19, p = .04).
Figure 3 depicts the extent of clinically meaningful change in fatigue from baseline to 6 
months and baseline to 12 months. The criterion for clinically meaningful change in fatigue 
over time was met among 30% of men in the ADT+ group versus 15% of men in the control 
group from baseline to 6 months, (χ2 = 4.87, p = .03). Similarly, 28% of men in the ADT+ 
group versus 14% of men in the control group met this criterion from baseline to 12 months, 
(χ2 = 4.54, p = .03).
Demographic and Clinical Predictors of Changes in Fatigue
Based on the patterns of change in fatigue observed, analyses were conducted to explore 
baseline demographic and clinical predictors (shown in Table 1) of change over time in 
fatigue severity, interference, and duration (number of days fatigued, amount of fatigue per 
day) among men in the ADT+ group. None of the variables examined (see Table 1) 
predicted changes in fatigue severity over time (p values > .05). Increases in fatigue 
interference were predicted by greater baseline medical comorbidities (β = .233, p = .04). In 
addition, increases in the number of days fatigued were predicted by higher baseline 
Gleason scores (β = .293, p = .01).
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Discussion
Results confirmed the hypothesis that prostate cancer patients receiving ADT would report 
worsening fatigue over time compared to prostate cancer patients not receiving ADT and 
men with no history of cancer. This pattern was evident on measures of fatigue severity, 
interference, and duration. Consistent with these changes, significant differences between 
ADT patients and controls were evident on measures of fatigue interference and duration at 
6 months and remained significantly different at 12 months. Significant differences between 
ADT patients and controls were evident on fatigue severity solely at 12 months. This pattern 
of results is consistent with those obtained by Alibhai and colleagues [9] who observed a 
decrease in vitality among men receiving ADT, but not among a prostate cancer and healthy 
control group.
Findings also confirmed the hypothesis that prostate cancer patients receiving ADT would 
report greater increases over time in clinically meaningful fatigue compared to prostate 
cancer patients not receiving ADT and men with no history of cancer. Over the 12-month 
followup period, rates of clinically meaningful fatigue (i.e., scores ≥ 4) increased by 20% in 
ADT−treated patients versus 3% in controls. Consistent with these changes, a significantly 
higher percentage of ADT−treated patients than controls reported clinically meaningful 
fatigue at 6 months (33% vs 21%) and 12 months (32% vs. 19%). These figures are less than 
the 43% rate of clinically meaningful fatigue cases observed in a cross-sectional study of 
ADT−treated patients conducted by Storey and colleagues [8]. Discrepant findings may be 
partially explained by differences in methodology. For example, Storey et al. defined 
clinically meaningful fatigue as scores greater than 3 on a 0 to 10 scale, rather than scores 
greater than 4 as in our study, and sampled patients who had been receiving ADT treatments 
for longer (median 26 months) than in the present study (up to 12 months). Additional 
findings in the present study showed that clinically meaningful (i.e., 1 SD or greater) 
increases in fatigue between baseline and 6 months and baseline and 12 months were more 
likely to occur in the ADT−treated patients than controls.
Results of the exploratory analyses indicated that a greater number of comorbidities at 
baseline predict a worsening trajectory of fatigue interference among men receiving ADT. 
There is some prior evidence that clinically relevant fatigue may be more common among 
ADT recipients with greater concurrent co-morbidities [8]. The present study also identified 
an association between a higher baseline Gleason score and greater increases in the number 
of days fatigued raising the possibility that worsening fatigue may be due in part to advanced 
disease rather than ADT per se. To the best of our knowledge, this relationship has not been 
reported previously. Taken together, these findings highlight the need for additional research 
on risk factors for fatigue among ADT recipients and research on the mechanisms by which 
these risk factors influence fatigue among ADT recipients.
The current study is the first prospective, longitudinal study to investigate fatigue among 
men receiving ADT relative to both men with prostate cancer receiving prostatectomy only 
as well as men with no history of cancer. Moreover, we utilized a multidimensional measure 
of fatigue that allowed us to assess fatigue severity, the extent to which fatigue interfered 
with daily life, the duration of fatigue symptoms, and clinically significant fatigue. However, 
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there were some limitations to the current project. First, this is an observational study and 
therefore we cannot determine with certainty that differences between groups in fatigue were 
due solely to ADT administration. Second, we acknowledge that other cut points may have 
been chosen to identify clinically meaningful fatigue; however, there is precedent for use of 
4 as a cut point [14]. Third, patients were followed for only twelve months following ADT 
initiation. Future studies should follow patients over longer periods of time and should also 
examine the impact of ADT discontinuation on fatigue levels. Fourth, the present study 
examined only clinical and demographic variables as potential predictors of changes in 
fatigue over time in ADT−treated patients. Future studies should examine a broader range of 
potential predictors (e.g., psychosocial characteristics, genetic polymorphisms).
Studies investigating fatigue management among men receiving ADT have focused largely 
on physical activity interventions such as aerobic and resistance exercise. Many of these 
intervention studies have reported improvements in fatigue among participants receiving the 
intervention, suggesting that physical activity interventions are capable of reducing 
symptoms of fatigue among men receiving ADT [18–20]. While findings such as these are 
encouraging, other studies have failed to show improvements in fatigue [21–23] indicating 
that further research is needed to understand under what circumstances these interventions 
are effective. Additional behavioral interventions that have been shown to mitigate persistent 
fatigue in people with cancer and warrant further investigation include energy conservation 
[23] and cognitive-behavior therapy [24–25]. Moreover, pharmacologic interventions, such 
as methylphenidate or methylprednisolone for short-term use, among select patients may 
also be a viable option [26–27]. Despite the strategies employed, fatigue remains one of the 
most commonly reported symptoms among men receiving ADT. It is clear that further 
research is needed to determine effective strategies for fatigue management.
In summary, these findings suggest that prostate cancer patients receiving ADT experience 
high levels of fatigue that is clinically meaningful during the 12 months following ADT 
initiation. Patients appear to be particularly at risk for increases in fatigue between ADT 
initiation and 6 months post-initiation. In addition, several baseline risk factors have been 
identified, highlighting important time points for screening and implementation of cognitive-
behavioral or pharmacological interventions aimed at fatigue reduction.
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Fig 1. 
Adjusted mean estimates from mixed model analysis covarying for race, marital status, 
education, and comorbidities.
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Fig 2. 
Percentage of patients with clinically meaningful fatigue, defined as scores ≥ 4 for the 
average of the fatigue severity items. The figure depicts raw percentages.
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Fig 3. 
Percentage of patients with clinically meaningful change in fatigue, defined as 1SD change, 
from baseline to 6 months and from baseline to 12 months.
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